SHANGHAI FUDAN H YC-,10 (F:FDY) — Market Cap & Net Worth
Market Cap & Net Worth: SHANGHAI FUDAN H YC-,10 (FDY)
SHANGHAI FUDAN H YC-,10 (F:FDY) has a market capitalization of $109.71 Million (€93.84 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #18947 globally and #1743 in its home market, demonstrating a 2.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANGHAI FUDAN H YC-,10's stock price €0.28 by its total outstanding shares 340000000 (340.00 Million). Also see SHANGHAI FUDAN H YC-,10 asset portfolio for a full breakdown of the balance sheet.
SHANGHAI FUDAN H YC-,10 Market Cap History: 2020 to 2026
SHANGHAI FUDAN H YC-,10's market capitalization history from 2020 to 2026. Data shows growth from $43.80 Million to $109.71 Million (16.69% CAGR). Also see FDY cash flow metrics for how efficiently the company converts equity into cash flow.
SHANGHAI FUDAN H YC-,10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANGHAI FUDAN H YC-,10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SHANGHAI FUDAN H YC-,10 (FDY) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.18x
SHANGHAI FUDAN H YC-,10's market cap is 0.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $55.37 Million | $1.14 Billion | $213.30 Million | 0.05x | 0.26x |
| 2022 | $68.89 Million | $1.03 Billion | $138.00 Million | 0.07x | 0.50x |
| 2023 | $63.16 Million | $850.73 Million | $108.63 Million | 0.07x | 0.58x |
| 2024 | $117.66 Million | $709.40 Million | $39.73 Million | 0.17x | 2.96x |
| 2025 | $123.22 Million | $685.80 Million | -$157.44 Million | 0.18x | N/A |
Competitor Companies of FDY by Market Capitalization
Companies near SHANGHAI FUDAN H YC-,10 in the global market cap rankings as of September 20, 2026. Review SHANGHAI FUDAN H YC-,10 (FDY) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SHANGHAI FUDAN H YC-,10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
SHANGHAI FUDAN H YC-,10 Historical Marketcap From 2020 to 2026
Between 2020 and today, SHANGHAI FUDAN H YC-,10's market cap moved from $43.80 Million to $ 109.71 Million, with a yearly change of 16.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €109.71 Million | -10.97% |
| 2025 | €123.22 Million | +4.73% |
| 2024 | €117.66 Million | +86.28% |
| 2023 | €63.16 Million | -8.31% |
| 2022 | €68.89 Million | +24.41% |
| 2021 | €55.37 Million | +26.41% |
| 2020 | €43.80 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of SHANGHAI FUDAN H YC-,10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $109.71 Million USD |
| MoneyControl | $109.71 Million USD |
| MarketWatch | $109.71 Million USD |
| marketcap.company | $109.71 Million USD |
| Reuters | $109.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more